Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76


Adjudication of bleeding outcomes in an international thromboprophylaxis trial in critical illness.

Arnold DM, Lauzier F, Rabbat C, Zytaruk N, Barlow Cash B, Clarke F, Heels-Ansdell D, Guyatt G, Walter SD, Davies A, Cook DJ; PROTECT Investigators, on behalf of the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group..

Thromb Res. 2013 Mar;131(3):204-9. doi: 10.1016/j.thromres.2012.12.005. Epub 2013 Jan 12.


Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis.

Lauzier F, Arnold DM, Rabbat C, Heels-Ansdell D, Zarychanski R, Dodek P, Ashley BJ, Albert M, Khwaja K, Ostermann M, Skrobik Y, Fowler R, McIntyre L, Nates JL, Karachi T, Lopes RD, Zytaruk N, Finfer S, Crowther M, Cook D.

Intensive Care Med. 2013 Dec;39(12):2135-43. doi: 10.1007/s00134-013-3044-3. Epub 2013 Aug 14.


Heparin-induced thrombocytopenia in the critically ill: interpreting the 4Ts test in a randomized trial.

Crowther M, Cook D, Guyatt G, Zytaruk N, McDonald E, Williamson D, Albert M, Dodek P, Finfer S, Vallance S, Heels-Ansdell D, McIntyre L, Mehta S, Lamontagne F, Muscedere J, Jacka M, Lesur O, Kutsiogiannis J, Friedrich J, Klinger JR, Qushmaq I, Burry L, Khwaja K, Sheppard JA, Warkentin TE; PROTECT collaborators.; Canadian Critical Care Trials Group.; Australian and New Zealand Intensive Care Society Clinical Trials Group..

J Crit Care. 2014 Jun;29(3):470.e7-15. doi: 10.1016/j.jcrc.2014.02.004. Epub 2014 Feb 14.


Dalteparin versus unfractionated heparin in critically ill patients.

PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group., Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, Zytaruk N, Crowther M, Geerts W, Cooper DJ, Vallance S, Qushmaq I, Rocha M, Berwanger O, Vlahakis NE.

N Engl J Med. 2011 Apr 7;364(14):1305-14. doi: 10.1056/NEJMoa1014475. Epub 2011 Mar 22.


Bleeding during critical illness: a prospective cohort study using a new measurement tool.

Arnold DM, Donahoe L, Clarke FJ, Tkaczyk AJ, Heels-Ansdell D, Zytaruk N, Cook R, Webert KE, McDonald E, Cook DJ.

Clin Invest Med. 2007;30(2):E93-102.


Event adjudication and data monitoring in an intensive care unit observational study of thromboprophylaxis.

Cook D, Sinuff T, Zytaruk N, Rabbat C, Lee A, O'Donnell M, Thabane L, Linkins L, Treleaven D, Patel R, Meade M, Crowther M, Marshall JC, Douketis J; DIRECT Investigators and Canadian Critical Care Trials Group..

J Crit Care. 2009 Jun;24(2):168-75. doi: 10.1016/j.jcrc.2009.01.010. Epub 2009 Mar 27.


Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study.

Cook DJ, Rocker G, Meade M, Guyatt G, Geerts W, Anderson D, Skrobik Y, Hebert P, Albert M, Cooper J, Bates S, Caco C, Finfer S, Fowler R, Freitag A, Granton J, Jones G, Langevin S, Mehta S, Pagliarello G, Poirier G, Rabbat C, Schiff D, Griffith L, Crowther M; PROTECT Investigators.; Canadian Critical Care Trials Group..

J Crit Care. 2005 Dec;20(4):364-72.


An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial.

Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B, Andrew M; REVIVE Study Group..

Thromb Res. 2003 Jan 25;109(2-3):85-92.


Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.

Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV; CORTES Investigators. Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety..

N Engl J Med. 2001 Mar 1;344(9):626-31.


Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.

Sobieraj DM, Coleman CI, Tongbram V, Chen W, Colby J, Lee S, Kluger J, Makanji S, Ashaye A, White CM.

Pharmacotherapy. 2012 Sep;32(9):799-808. doi: 10.1002/j.1875-9114.2012.01106.x. Epub 2012 Jun 28. Review.


Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism.

Wellington K, McClellan K, Jarvis B.

Drugs. 2001;61(8):1185-209. Review.


Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).

Haas S, Breyer HG, Bacher HP, Fareed J, Misselwitz F, Victor N, Weber J; ECHOS Trial Group..

Int Angiol. 2006 Dec;25(4):335-42.


PROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis plan.

Cook D, Meade M, Guyatt G, Walter SD, Heels-Ansdell D, Geerts W, Warkentin TE, Cooper DJ, Zytaruk N, Vallance S, Berwanger O, Rocha M, Qushmaq I, Crowther M.

J Crit Care. 2011 Apr;26(2):223.e1-9. doi: 10.1016/j.jcrc.2011.02.010.


Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.

Beyer-Westendorf J, Lützner J, Donath L, Tittl L, Knoth H, Radke OC, Kuhlisch E, Stange T, Hartmann A, Günther KP, Weiss N, Werth S.

Thromb Haemost. 2013 Jan;109(1):154-63. doi: 10.1160/TH12-07-0510. Epub 2012 Nov 29.


Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review.

Ribic C, Lim W, Cook D, Crowther M.

J Crit Care. 2009 Jun;24(2):197-205. doi: 10.1016/j.jcrc.2008.11.002. Epub 2009 Feb 7. Review.


Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial.

McLeod RS, Geerts WH, Sniderman KW, Greenwood C, Gregoire RC, Taylor BM, Silverman RE, Atkinson KG, Burnstein M, Marshall JC, Burul CJ, Anderson DR, Ross T, Wilson SR, Barton P; Canadian Colorectal Surgery DVT Prophylaxis Trial investigators..

Ann Surg. 2001 Mar;233(3):438-44.


Supplemental Content

Support Center